NCT06735625Recruiting
Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"
Source: ClinicalTrials.gov · Last updated 2 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patients
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 11 Dec 2024
- Start date
- 6 Mar 2025
- Primary completion date
- 20 Mar 2026
- Lead sponsor
- Centre Hospitalier de Saint-Denis
- Diseases
- Sickle cell disease
- NCT number
- NCT06735625
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 6 Mar 2025 to the primary completion date, 20 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known hyper or hypothyroidism or subject treated with levothyroxine
- Oral corticosteroid therapy in progress
Other illness
- Hemoglobinopathies other than sickle cell disease (Criteria for Control Patients)
- Chronic active viral disease: hepatitis B, C, HIV
- Current infections or known inflammatory pathologies
Lab values
- Hemoglobin disorder other than sickle cell disease (Criteria for Sickle Cell Patients)
Other
- Transfusion less than 3 months ago
- Active tumor pathology or remission for less than 5 years
- Participation in interventional biomedical research
- Opposition to participation in research by the patient if he is an adult, or by one of the two parents if the patient is a minor.
- Non-affiliation to a social security system
Who the study is looking for
- Adults: \> 15 years and 6 months
- Pediatrics: ≥ 3 years and ≤ 15 years and 6 months
- Known SS or Sβ0 phenotypes
- 1 -Adults: \> 15 years and 6 months /Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration
- -Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder
- 4-Blood sample planned as part of medical care
Age in the registry: 3 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier de Saint-Denis Coordinator of this site? Confirm its status | Saint-Denis | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.